Month: October 2026

Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET

NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and David Hastings, Chief Financial Officer, will participate in a fireside chat at the Stifel 2026 Healthcare Conference on Wednesday, November 11, at 10:00 a.m. ET. The conference will be held from November 10-12 in New York, and Ms. Good and Mr. Hastings will also participate in investor meetings with attendees.

To register for the fireside chat virtually, click here.

About Trevi Therapeutics, Inc.       
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). In clinical trials, Haduvio showed a statistically-significant reduction in cough frequency, consistent across baseline cough frequencies, and showed improvements in patient-reported outcomes, in both patients with IPF-related chronic cough and in patients with RCC. Haduvio is believed to act on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.   

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~140,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients’ quality of life.       
    
RCC is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.      

The FDA has conditionally approved Haduvio as the trade name for nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.    
    
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.    

Investor Contact     
Jonathan Carlson     
Trevi Therapeutics, Inc.     
(203) 654 3286     
IR@trevitx.com  
  
Media Contact     
Rosalia Scampoli     
914-815-1465     
rscampoli@marketcompr.com     

Private equity operations expert brings more than 20 years of experience helping investors and portfolio companies improve EBITDA, optimize operations and accelerate enterprise value creation

WASHINGTON, D.C., Oct. 27, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Neel Malkani as an Executive Vice President within the firm’s Corporate Finance segment.

Mr. Malkani, who is based in Washington, D.C., brings more than 20 years of experience helping management teams improve financial and operational performance across the investment lifecycle. He has advised clients on diligence, post-close value creation, performance improvement and exit readiness initiatives, helping organizations translate operational opportunities into measurable EBITDA growth and enterprise value creation.

In his role at FTI Consulting, he will advise investors, lenders, boards and chief executives with a focus on value creation and performance enhancement initiatives.

“Our private capital clients continue to seek operational levers that create measurable value throughout the deal lifecycle,” said Scott Bingham, Co-Leader of U.S. Corporate Finance and Global Co-Leader of Transactions. “Neel has a proven track record helping sponsors and management teams identify and execute opportunities to improve EBITDA, strengthen supply chains, optimize operations and accelerate enterprise value creation. His addition reinforces our ability to help clients navigate complex transformation challenges and deliver sustainable performance improvements.”

Prior to joining FTI Consulting, Mr. Malkani served as managing director, Private Capital at Maine Pointe. Earlier in his career, he held leadership positions at Clarendon Partners, DB&A, High Performance Technologies and Accenture, leading commercial, client, and internal initiatives focused on measurable financial improvement and increased enterprise value.

Mr. Malkani has advised clients across industries including aerospace and defense, automotive and industrial, food and agribusiness, hospitality, gaming and leisure, retail and consumer products, transportation and logistics. His work has helped clients convert operational improvements into measurable financial results, including hundreds of millions of dollars in impact and stronger long-term business performance.

Commenting on his appointment, Mr. Malkani added, “Investors and management teams today are focused on achieving tangible results that improve performance and position businesses for long-term growth. FTI Consulting’s combination of transactions, transformation and turnaround expertise and deep industry knowledge creates a powerful platform for helping clients unlock value. I look forward to working with sponsors and corporate leaders to improve financial and operational performance, enhance profitability and create sustainable enterprise value.”

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.
555 12^th Street NW
Washington, DC 20004
+1.202.312.9100

Investor Contact:
Mollie Hawkes
+1.617.747.1791
mollie.hawkes@fticonsulting.com

Media Contact:
Nick Emmons
+1.617.510.1676
nick.emmons@fticonsulting.com

HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. 

Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. 

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.

Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website. 

About Harvard Bioscience 

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Company Contact:
Mark Frost
Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com

HOUSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) — Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) today announced that the High Court of Ireland has approved the previously announced scheme of arrangement through which the Company intends to change its legal domicile from Ireland to Delaware.

Weatherford expects to complete the redomestication on November 13, 2026, subject to the satisfaction of customary closing conditions. Upon completion, Weatherford International Corp, a Delaware corporation, will become the publicly traded parent company of the Weatherford group.

The redomestication will not change the Company’s operations, management, business strategy or headquarters. Weatherford’s shares are expected to continue trading on the Nasdaq Global Select Market under the ticker symbol “WFRD.”

Additional information regarding the redomestication is available in Weatherford’s filings with the U.S. Securities and Exchange Commission.

About Weatherford

Weatherford is a global energy services company that helps customers drill smarter, complete wells more effectively, and maximize production across the entire well lifecycle. With a differentiated portfolio of market-leading solutions, integrated technologies, and a broad global customer footprint across six continents, we blend advanced engineering, digital intelligence, and world-class field expertise to reduce risk, improve performance, and maximize the value of customer assets. Together, we elevate every operation, delivering stronger wells, sharper decisions, and better energy for the world. Visit weatherford.com for more information and connect with us on social media.

Forward-Looking Statements
This release, as well as other statements we make, includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements that are not historical facts, including statements about Weatherford’s beliefs, plans, estimates, or expectations, are forward-looking statements. Forward-looking statements often use words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “plan,” “potential,” “should,” “target,” “will,” and other words of similar meaning. Such forward-looking statements include, but are not limited to, statements regarding the Redomestication, the related restructuring activities and the expected timing and financial implications. These statements are based on current beliefs, plans, estimates, and expectations, all of which involve risk and uncertainty. Actual results may differ materially from those included in such forward-looking statements and therefore you should not place undue reliance on them.

The factors that could cause actual results to differ materially from current expectations include, but are not limited to, our ability to satisfy the conditions to the Redomestication within the expected timeframe or at all; our ability to realize the expected benefits from the Redomestication; the occurrence of difficulties in connection with the Redomestication, including any costs related thereto; the risk that the Redomestication disrupts current plans and operations; any changes in tax laws, tax treaties or tax regulations or the interpretation or enforcement thereof by the tax authorities in Ireland, the United States and other jurisdictions following the Redomestication; and the future financial performance of Weatherford following the Redomestication.

The foregoing factors are in addition to those other risks, uncertainties, and factors included in the “Risk Factors” section and elsewhere in Weatherford’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and other documents filed with the SEC. There may be other risks and uncertainties that we are not currently aware of or are unable to predict and which may also affect Weatherford’s forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements and Weatherford undertakes no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

For Investors:

Luke Lemoine

Senior Vice President, Corporate Development & Investor Relations

+1 713-836-7777

investor.relations@weatherford.com 

For Media:

Kelley Hughes

Vice President, Communications, Marketing & Sustainability

media@weatherford.com 

Latest DSP integration expands buyer access to OptimizeRx point of care inventory through existing programmatic workflows

WALTHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a healthcare technology company helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced a new partnership with PulsePoint, an award-winning programmatic platform advancing omnichannel healthcare marketing, that will make OptimizeRx’s authenticated electronic health record (EHR) and e-prescribing inventory available to PulsePoint clients.

The integration builds on both companies’ efforts to make HCP media more connected. OptimizeRx is expanding programmatic access to point of care inventory that historically was only purchased through direct or specialized channels, while PulsePoint brings that inventory and 250,000 incremental NPIs into its platform designed to coordinate HCP media activation, optimization, and reporting. Together, the companies are making point of care easier to incorporate into the broader media plan rather than managing it as a separate buy.

Reducing Fragmentation Across the HCP Media Plan

The partnership helps close a longstanding gap in omnichannel HCP marketing. Digital HCP media can build awareness and consideration over time. The EHR adds a lower-funnel layer closer to prescribing, delivering relevant information within the clinical workflow. Yet EHR media has historically been planned and purchased separately from other digital channels. By bringing OptimizeRx inventory into PulsePoint, marketers can more easily extend broader HCP campaigns into EHR and e-prescribing workflows within a connected programmatic strategy.

“Omnichannel gets harder when high-value channels live in separate buying environments,” said Stephen Silvestro, CEO of OptimizeRx. “Our work with PulsePoint removes a layer of fragmentation, making it easier for brands and agencies to put point of care to work alongside the rest of their media investments.”

“OptimizeRx extends the scale of in-workflow EHR engagement we can offer clients to fuel their comprehensive omnichannel HCP strategies,” said Keith Matt, Group Vice President of Sales at PulsePoint. “Paired with our broader EHR footprint and real-time activation, optimization, and reporting, clients get more reach, more control, and clearer visibility across every campaign.”

Extending Programmatic Reach at the Point of Care

PulsePoint is among the first DSPs to integrate OptimizeRx’s authenticated EHR inventory since OptimizeRx opened its network to programmatic buying in June 2026. The integration will give PulsePoint clients access to incremental NPIs through OptimizeRx’s point of care network and bring PulsePoint’s programmatic EHR reach to over 1 million NPIs. OptimizeRx’s authenticated EHR inventory is expected to be available to advertisers using PulsePoint in November 2026.

About OptimizeRx

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood^® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on X or LinkedIn, or visit www.optimizerx.com.

About PulsePoint

PulsePoint, a division of Internet Brands, is an award-winning technology company that uses real-world data in real time to optimize campaign performance and revolutionize health decision-making. Leveraging proprietary datasets and methodology, PulsePoint helps brands engage healthcare professionals and consumer populations with an unprecedented level of accuracy to deliver unparalleled results to the clients it serves. For more information, visit pulsepoint.com.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “will”, “is”, “brings”, “helps”, “removes”, “extends”, “improve” or other similar words and expressions are intended to identify these forward-looking statements. All statements in this press release that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the ability to make HCP media more connected, the Company’s efforts to make point of care easier to incorporate into the broader media plan and remove fragmentation, the ability to close a longstanding gap in omnichannel HCP marketing, the ability of digital HCP media to build awareness and consideration over time, the ability of marketers to more easily extend broader HCP campaigns into EHR and e-prescribing workflows within a connected programmatic strategy, the Company’s ability to remove fragmentation making it easier for brands and agencies to put point of care to work alongside other media investments, the ability of clients to get more reach, more control, or clearer visibility across every campaign, and the ability to increase PulsePoint clients’ programmatic EHR reach to over 1 million NPIs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with eRx platforms and EHR networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law. 

OptimizeRx Contact
Jennifer Dinkel, SVP Marketing
jdinkel@optimizerx.com

OptimizeRx Investor Relations Contact
Douglas Farrell
LifeSci Advisors, LLC
dfarrell@lifesciadvisors.com

OptimizeRx Press Inquiries
Matter Communications
optimizerx@matternow.com

OptimizeRx Partnership Inquiries
Louis Trivento, SVP Strategic Partnerships
ltrivento@optimizerx.com

PulsePoint Media Contact
Alia Paavola
apaavola@pulsepoint.com

MONTREAL, Oct. 27, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) announced today that its Board of Directors has approved a monthly dividend of C$0.01333 per common share (C$0.16 annually) for November 2026. This will be payable on November 17, 2026, to shareholders of record as of the close of business on November 9, 2026.

The Corporation’s monthly dividend qualifies as an “eligible dividend” for Canadian income tax purposes. The payment and increase of dividends are at the discretion of the Board and will depend on the Corporation’s financial results, cash requirements, prospects and other factors deemed relevant by the Board.

About Dynacor

Dynacor Group is an ore processing company dedicated to producing gold sourced from artisanal miners. Since its establishment in 1996, Dynacor has pioneered a responsible mineral supply chain with stringent traceability and audit standards for the fast-growing artisanal mining industry. By focusing on formalized miners, the Canadian company offers a win-win approach for governments and miners globally. Dynacor operates the Veta Dorada plant and owns a gold exploration property in Peru. The company is expanding to West Africa and within Latin America.

The premium paid by luxury jewellers for Dynacor’s PX Impact® gold goes to Fidamar Foundation, an NGO that mainly invests in health and education projects for artisanal mining communities in Peru. Visit www.dynacor.com for more information.

Forward-Looking Information

Certain statements in the preceding may constitute forward-looking statements, which involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Dynacor, or industry results, to be materially different from any future result, performance or achievement expressed or implied by such forward-looking statements. These statements reflect management’s current expectations regarding future events and operating performance as of the date of this news release.

Contact:

For more information, please contact:

Ruth Hanna
Director, Investor Relations
T: 514-393-9000 #236
E: investors@dynacor.com
Website: https://dynacor.com

Renmark Financial Communications Inc.
Bettina Filippone
T: (416) 644-2020 or (212) 812-7680
E: bfilippone@renmarkfinancial.com
Website: www.renmarkfinancial.com

• A consortium led by Novacium, together with Axel’One and AD-VENTA, has secured funding from the Defence Innovation Agency (AID) and the Directorate General of Armaments (DGA) under the RAPID program (Support Scheme for Dual-Use Innovation), a program known for its selectivity.
• The METAGENE™ project:
  • Aims to develop a self-contained, high-pressure green hydrogen production station using a solid, non-hazardous metallic fuel.
  • With a budget of €1.2 million, the project is subsidized at the maximum rate of 80% provided under the program and began on September 1, 2026.

MONTREAL and SOLAIZE, France, Oct. 27, 2026 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (TSX-V: HPQ, OTCQB: HPQFF, FRA: O08) is pleased to inform its shareholders that its strategic partner, NOVACIUM SAS, a French deep-tech company specializing in green engineering of materials for energy applications, announces that the METAGENE™ project consortium, which it leads alongside Axel’One and AD-VENTA, has been awarded funding by the AID and DGA under the RAPID program. The funding agreement was finalized in June 2026 and could not be made public before today for confidentiality reasons.

The METAGENE™ project (from “METAux pour l’hydroGENE,” meaning “metals for hydrogen”) aims to develop and validate a self-contained, high-pressure green hydrogen production station, advancing the technology from Technology Readiness Level (TRL) 3 to TRL 5–6. The 30-month project began on September 1, 2026. Its budget totals €1.2 million, subsidized at the program’s maximum rate of 80%, representing nearly €1 million in public funding. The first funding payment was made in summer 2026.

Image 1) Conceptual rendering of a hydrogen production and dispensing station adapted to the METAGENE process

A selective program supporting dual-use innovation

The RAPID program is implemented by the AID, drawing on the technical expertise of the DGA. It supports industrial research and experimental development projects with strong technological potential and dual military and civilian applications. Known for its demanding standards and often described as a genuine innovation competition, it selects only a limited number of projects each year and can subsidize up to 80% of eligible expenses. Selecting the METAGENE™ consortium at the maximum funding rate reflects the authorities’ confidence in the technology’s dual-use potential.

METAGENE™: an innovative, patented process for producing green hydrogen without electricity

METAGENE™ is an innovative, patented process for producing green hydrogen without electricity, designed for both civilian and military uses. Hydrogen is produced at the point of use from a solid metallic fuel based on aluminum and silicon, which releases hydrogen when it contacts water in the presence of an activator. Unlike electrolysis, the reaction requires no electricity source and generates no greenhouse gases; it produces an inert solid by-product. In its solid bulk form, the fuel is inert and not classified as a hazardous material, which considerably simplifies transportation and storage. With a high energy density of about 1.25 m³ of hydrogen per kilogram of fuel, METAGENE™ offers an alternative to conventional hydrogen production and transportation.

Image 2) Photograph of the solid fuel made from recycled aluminum and silicon developed by Novacium

This technology has already been the subject of two industrial partnerships: a memorandum of understanding with recycled aluminum producer GLD Alloys in April 2025, aimed at securing a supply of low-carbon aluminum for the fuel, and an industrial cooperation agreement with AD-VENTA in December 2025, concerning the integration of the METAGENE™ reactor into a high-pressure hydrogen dispensing station capable of delivering up to 20 kg of hydrogen per day. RAPID funding will support the development and validation phase of this station.

A consortium bringing together complementary expertise

The project brings together three partners with complementary expertise. Novacium, the consortium leader, develops the metallic fuel and hydrogen generation reactor and manages the project. AD-VENTA, a specialist in high-pressure hydrogen systems, is adapting its compression and dispensing station to integrate this reactor. Axel’One, a collaborative platform dedicated to chemistry and the environment, contributes its gas analysis and characterization capabilities, along with its experience in reactors and hydrogen purification.

“Being selected by the AID and DGA under a program as demanding as RAPID is recognition of our teams’ work and the strength of our consortium,” said Dr. Jed Kraiem, co-founder and Chief Operating Officer of Novacium. “Together with Axel’One and AD-VENTA, we bring together all the expertise required, from fuel chemistry to the high-pressure station, to take METAGENE™ from the laboratory to an operational demonstrator.”

“METAGENE™ is particularly well suited to decentralized high-pressure hydrogen production in remote environments,” added Jean-Luc Mussot, President and Chief Executive Officer of AD-VENTA. “This funding will enable us to integrate Novacium’s reactor into our dispensing station and validate its performance under real-world conditions.”

Strong economic potential in growing civilian and military markets

Beyond its technological dimension, METAGENE™ targets rapidly growing markets. The global green hydrogen market could reach approximately US$500 billion by 2030 (source: BloombergNEF). In the mobility segment alone, the hydrogen market is estimated at approximately €25 billion by that time, while autonomous energy systems for defence applications (drones, vehicles and bases) represent an estimated market of €5 billion to €10 billion.

METAGENE™’s positioning rests on a tangible economic advantage. By producing hydrogen at the point of use, without electricity or major infrastructure, the solution avoids the costs and constraints associated with transporting and storing pressurized hydrogen, which today often exceed €50/kg. The fuel uses abundant, low-cost metals, aluminum and silicon, with a raw material cost of approximately €20 to €30 per kilogram of hydrogen produced on site.

These advantages address practical needs expressed by numerous sectors: powering inspection and surveillance drones, communication stations and remote outposts, off-grid industrial sites, clean mobility, and autonomous defence bases and systems operating in challenging environments. These are all applications in which decentralized, safe and competitive hydrogen production provides a decisive advantage.

About Novacium SAS

Novacium is a French deep-tech company based in Solaize, specializing in developing and producing silicon-based anode materials for lithium-ion batteries through a proprietary process. Novacium also designs custom battery cells and packs for demanding applications, particularly in the defence, aerospace and portable-energy sectors.

About HPQ Silicon

HPQ Silicon Inc. is a Quebec-based industrial issuer listed on the TSX Venture Exchange (TSX-V: HPQ), focused on innovation in advanced materials and the development of critical processes.

HPQ holds a strategic 36.8% interest in Novacium, its research, development and commercialization partner. Together, HPQ and Novacium are developing next-generation silicon-based anode materials (GEN3 and GEN4) for batteries, pursuing commercialization of ENDURA+ lithium-ion cells, and developing innovative technologies for clean hydrogen production and energy recovery from residual materials. HPQ holds the exclusive commercialization rights to these technologies in North America.

About AD-VENTA

AD-VENTA is an innovative French company specializing in the design and manufacture of high-pressure hydrogen storage, regulation and dispensing systems, including pressure regulators, smart valves and cylinder heads for mobile applications. Based in Châteauneuf-sur-Isère (Drôme), it provides turnkey solutions for hydrogen mobility (light vehicles, aviation and marine applications) and has recognized expertise in gas safety and regulations.

About Axel’One

Axel’One is a collaborative platform dedicated to chemistry and the environment, established in 2011 in the Auvergne-Rhône-Alpes region. It supports R&D projects and very small, small and medium-sized enterprises in advanced materials and innovative processes by providing offices, laboratories, technology halls and scale-up pilot facilities, as well as research and characterization services. It has a team of approximately 30 people.

Cautionary Note Regarding Forward-Looking Information

This news release contains forward-looking statements based on certain assumptions regarding technological performance, market demand, permits, financing, supply chains and economic conditions. These statements involve significant risks, including delays, regulatory issues, competition, the availability of financing and macroeconomic uncertainties. Actual results could differ materially from those anticipated. Detailed risk factors are presented in HPQ’s annual information form available on SEDAR+.

Forward-looking statements are provided solely to outline management’s future expectations and objectives. A more detailed cautionary note regarding forward-looking information related to the METAGENE™ technology is available for download [here]. 

Additional information regarding the Company is available in the SEDAR+ database (www.sedarplus.ca) and on the Company’s website at www.hpqsilicon.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Information

NOVACIUM	HPQ Silicon
Dr. Jed Kraiem, Ph.D., COO	Bernard J. Tourillon, BAA, MBA, CEO
info@novacium.com	info@hpqsilicon.com

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/64fe712c-6993-4e12-a6a6-2e29dab0aaff
https://www.globenewswire.com/NewsRoom/AttachmentNg/dfcf9013-3617-45f3-81c7-3e0bd6ca6d6f